BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 172 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,933,096 | +0.6% | 555,522 | 0.0% | 1.21% | -58.1% |
| Q2 2023 | $3,910,875 | -15.6% | 555,522 | 0.0% | 2.88% | -35.7% |
| Q1 2023 | $4,633,053 | -31.0% | 555,522 | -5.1% | 4.48% | -20.0% |
| Q4 2022 | $6,718,027 | -18.9% | 585,194 | -33.9% | 5.60% | +19.1% |
| Q3 2022 | $8,284,000 | +17.6% | 885,194 | -7.2% | 4.71% | +119.9% |
| Q2 2022 | $7,046,000 | -75.9% | 953,994 | -58.0% | 2.14% | -63.0% |
| Q1 2022 | $29,242,000 | +19.2% | 2,270,733 | -4.2% | 5.78% | +65.9% |
| Q4 2021 | $24,523,000 | -11.7% | 2,370,733 | +14.5% | 3.48% | +0.8% |
| Q3 2021 | $27,777,000 | -8.5% | 2,070,733 | +7.8% | 3.46% | -17.4% |
| Q2 2021 | $30,367,000 | +26.1% | 1,920,733 | -18.9% | 4.18% | +16.1% |
| Q1 2021 | $24,079,000 | +8.4% | 2,367,670 | -20.6% | 3.61% | +29.6% |
| Q4 2020 | $22,207,000 | +156.0% | 2,980,870 | +18.0% | 2.78% | +143.5% |
| Q3 2020 | $8,676,000 | -9.0% | 2,525,857 | +26.3% | 1.14% | -5.5% |
| Q2 2020 | $9,530,000 | – | 2,000,000 | – | 1.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |